


## BEST AVAILABLE COPY

Approved for use through 10/31/2002. GSA ECR-1-001  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 1 of 3

Attorney Docket No: 675.002US1

RECEIVED  
TECH CENTER 1600  
JAN 28 2003  
1600/2900

## US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
<i>JK</i>	US-5,993,388	11/30/1999	Kattan, M. W., et al	600	300	06/25/1998
<i>JK</i>	US-6,409,664	06/25/2002	Kattan, M. W., et al	600	300	11/24/1999

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
<i>JK</i>	WO-00/63841	10/26/2000	Wilkinson, L.	G06T	11/00	
<i>JK</i>	WO-99/38011	07/29/1999	Pollack, M. N., et al	G01N	33/574	

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	REMARKS
<i>JK</i>	·	"Human IL-6 Immunoassay, For the quantitative determination of human Interleukin 6 soluble Receptor (IL-6 sR) concentrations in cell culture supernate, serum, plasma, and urine", Quantikine, Catalog Number DR600, pp. 1-15	<i>1/29 1999</i>
<i>JK</i>	·	"Human IL-6 Immunoassay, For the quantitative determination of human interleukin 6 (IL-6) concentrations in cell culture supernate, serum, and plasma", Quantikine, Catalog Number D6050, pp. 1-15	<i>JAN 1999</i>
<i>JK</i>	·	ADLER, H.L., et al., "Elevated Levels of Circulating Interleukin-6 and Transforming Growth Factor- $\beta$ 1 in Patients with Metastatic Prostatic Carcinoma", <u>The Journal of Urology</u> , 161, (January, 1999), pp. 182-187	
<i>JK</i>	·	AKIMOTO, S., et al., "Relationship Between Serum Levels of Interleukin-6, Tumor Necrosis Factor- $\alpha$ and Bone Turnover Markers in Prostate Cancer Patients", <u>Endocrine Journal</u> , Vol. 45, No. 2, (1998), pp. 183-189	
<i>JK</i>	·	BELLUCO, C., et al., "Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer", <u>Annals of Surgical Oncology</u> , Vol. 7, No. 1, (March, 2000), pp. 133-138	
<i>JK</i>	·	FIGUEROA, J.A., et al., "Differential Expression of Insulin-Like Growth Factor Binding Proteins in High Versus Low Gleason Score Prostate Cancer", <u>The Journal of Urology</u> , 159, (April, 1998), pp. 1379-1383	
<i>JK</i>	·	IVANOVIC, V., et al., "Elevated plasma levels of TGF- $\beta$ 1 in patients with invasive prostate cancer", <u>Nature Medicine</u> , Vol. 1, No. 4, (April 4, 1995), pp. 282-283	
<i>JK</i>	·	JUNKER, U., et al., "Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering From Renal Cell Carcinoma", <u>Cytokine</u> , Vol. 8, No. 10, (October, 1996), pp. 794-798	
<i>JK</i>	·	KAKEHI, Y., et al., "Serum TGF- $\beta$ 1 Levels in Patients with Prostatic Cancer: Positive Correlation with Metastasis and Inverse Correlation with Age", <u>Proceedings of the American Urological Association</u> , Vol. 155, abstract 435, (May, 1996), 1 page	

EXAMINER

DATE CONSIDERED


*2/18/03*

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 2 of 3

Attorney Docket No: 675.002US1

TECH CENTER 1600/2900

RECEIVED

JAN 28 2003

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
KJM	1	KATTAN, M.W., et al., "A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer", <u>Journal of the National Cancer Institute</u> , Vol. 90, No. 10, (May 20, 1998), pp. 766-771	
	2	KONG, FENG-MING, et al., "Elevated Plasma Transforming Growth Factor- $\beta_1$ Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor", <u>Ann. Surg.</u> , Vol. 222, No. 2, (1995), pp. 155-162	
	3	KRASAGAKIS, K., et al., "Elevated plasma levels of transforming growth factor (TGF)- $\beta_1$ and TGF- $\beta_2$ in patients with disseminated malignant melanoma", <u>British Journal of Cancer</u> , Vol. 77, No. 9, (1998), pp. 1492-1494	
	4	LANGE, I., et al., "Plasma-TGF- $\beta_1$ -Konzentrationen bei Patienten mit einem Prostatakarzinom oder einer benignen Prostatahyperplasie", <u>Der Urologe</u> , Vol. 37, (1998), pp. 199-202	With English Abstract
	5	NAKASHIMA, J., et al., "Serum Interleukin 6 as a Prognostic Factor in Patients with Prostate Cancer", <u>Clinical Cancer Research</u> , 6, (July, 2000), pp. 2702-2706	
	6	PERRY, K.T., et al., "Transforming Growth Factor Beta as a Clinical Biomarker for Prostate Cancer", <u>Urology</u> , Vol. 49, No. 1, (1997), pp. 151-155	
	7	SCAMBIA, G., et al., "Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer", <u>British Journal of Cancer</u> , (1995), pp. 354-356	
	8	SHARIAT, S.F., et al., "Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 with Prostate Cancer Invasion, Progression, and Metastasis", <u>Journal of Clinical Oncology</u> , 20, (February 1, 2002), pp. 833-841	
	9	SHARIAT, S.F., et al., "Plasma Levels of Interleukin-6 and Its Soluble Receptor are Associated with Prostate Cancer Progression and Metastasis", <u>Urology</u> , 58, (2001), pp. 1008-1015	
	10	SHARIAT, S.F., et al., "Preoperative Plasma Levels of Transforming Growth Factor $\beta_1$ (TGF- $\beta_1$ ) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy", <u>Journal of Clinical Oncology</u> , 19, (June 1, 2001), pp. 2856-2864	With Abstract
	11	SHIM, K.S., et al., "Elevated Serum Levels of Transforming Growth Factor- $\beta_1$ in Patients with Colorectal Carcinoma", <u>American Cancer Society</u> , (1999), pp. 554-561	
	12	SMITH, D.S., et al., "Longitudinal Screening for Prostate Cancer with Prostate-Specific Antigen", <u>JAMA</u> , Vol. 276, No. 16, (October, 1996), pp. 1309-1315	
	13	TSUSHIMA, H., et al., "High Levels of Transforming Growth Factor $\beta_1$ in Patients With Colorectal Cancer: Association With Disease Progression", <u>Gastroenterology</u> , Vol. 110, No. 2, (1996), pp. 375-382	
U	14	UEDA, T., et al., "Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis", <u>J Gastroenterol</u> , Vol. 29, (1994), pp. 423-429	
	15	WIKSTROM, P., et al., "Transforming Growth Factor beta1 is Associated with	

EXAMINER

DATE CONSIDERED

7/15/05

Substitute Disclosure Statement Form (PTO-1449)  
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached


**BEST AVAILABLE COPY**

Approved for use through 10/31/2002. OMB 651-0031  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin M.D., Kevin
Group Art Unit	1645
Examiner Name	Unknown

TECH CENTER 1600/2800

RECEIVED

JAN 28 2003

Sheet 3 of 3

Attorney Docket No: 675.002US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>†</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>SL</i>		Angiogenesis, Metastasis, and Poor Clinical Outcome in Prostate Cancer", <u>The Prostate</u> , 37, (1998), pp. 19-29	
<i>SL</i>		WOLFF, J.M., et al., "Serum Concentrations of Transforming Growth Factor- $\beta$ 1 in Patients with Benign and Malignant Prostatic Diseases", <u>Anticancer Research</u> , Vol. 19, (1999), pp. 2657-2659	
<i>SL</i>		WOLFF, J.M., et al., "Transforming growth factor-beta 1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia", <u>Br. J. Urol.</u> , Vol. 81, abstract, (1998), 1 page	
<i>SL</i>		WUNDERLICH, H., et al., "Serum Transforming Growth Factor- $\beta$ 1 in Patients with Renal Cell Carcinoma", <u>The Journal of Urology</u> , Vol. 157, (May, 1997), pp. 1602-1603	

EXAMINER

*Kevin Slawin*

DATE CONSIDERED

*7/18/03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>†</sup>Applicant's unique citation designation number (optional). <sup>‡</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute Disclosure Statement Form (PTO-1449)

611-5 JC100  
MAY 2, 2004  
PATENT & TRADEMARK OFFICE  
BEST AVAILABLE COPY

PTO-1449A (10-01)  
Approved for use through 10/31/2002. GMB 651-0031  
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin, Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 675.002US1

### US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
	WO 02/31209A	04/18/2002	Mousses, S., et al.	C12Q	1/68	

### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BOK, R. A., et al., "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of outcome in Hormone-Refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study", <u>Cancer Research</u> , 61(6), (March 15, 2001), pp. 2533-2536	
		DUQUE, J. I., et al., "Plasma Levels of Vascular Endothelial Growth Factor are Increased in Patients with metastatic Prostate Cancer", <u>Urology</u> , 54(3), (September 1999), pp. 523-527	
		GEORGE, D. J., et al., "Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-Refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480", <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> , 7(7), (July 2001), pp. 1932-1936	
		JONES, A., et al., "Elevated Serum Vascular Endothelial Growth Factor in Patients with Hormone-Escaped Prostate Cancer", <u>BJU International</u> , 85(3), (February 2000), pp. 276-280	

EXAMINER



DATE CONSIDERED

7/15/05

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached